Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations.
The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday.
Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said.
Photo: Sam Yeh, AFP
The company enrolled its first participant for the phase 3 trials in April 2019 and completed the enrollment of all participants in December that year, it said.
Participants were recruited in a randomized, double-blinded and placebo-controlled study, it added.
Participants were divided into three age groups: two months to six months old, six months to two years old, and two years to six years old, Medigen said.
The number of infants from two months to six months old accounted for 25 percent of all participants, it said.
The results showed the drug’s safety and tolerance were good, even for young participants, and there was no significant difference in safety and tolerance between participants who were given the vaccine and those who received a placebo, the company said.
As for immunogenicity, results showed that the seroprotection rates 28 days, six months and one year after two EV71 vaccination doses were higher than health authorities’ requirements, it said. The seroprotection rates refer to the degree of antibody prevalence.
In terms of efficacy, Medigen said that the experimental drug offered statistically significant protection against the enterovirus under the Poisson regression model.
As enterovirus infections are popular in Taiwan, China and Southeast Asia, the company hopes its vaccine can hit the market soon, as there are no EV71 vaccine products available in other parts of the world, except for China.
At present, only three Chinese manufacturers have launched enterovirus vaccines to be marketed locally in China, Medigen said.
Those vaccines are suitable for children over the age of six months, it said.
In 2018, the market sales of China’s EV71 vaccines reached more than NT$30 billion (US$1.08 billion), and about 21 million doses were sold per year on average in the past three years, Medigen said.
The company on June 10 reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine. It has applied to the Food and Drug Administration for emergency use authorization and is preparing to conduct phase 3 trials abroad.
Hon Hai Technology Group (鴻海科技集團), also known as Foxconn Technology Group (富士康科技集團) internationally, yesterday said it was confident that its performance would improve in the second half of this year. Investment plans related to electric vehicles (EVs) in different parts of the world are expected to gradually start coming to fruition, Hon Hai chairman Young Liu (劉揚偉) told reporters after leading a new year’s prayer at the company’s headquarters in New Taipei City’s Tucheng District (土城). Major challenges stemming from the COVID-19 pandemic and the Russia-Ukraine war continue to affect the global economy. However, Liu said that he expects a turnaround in
Singapore is seeing an influx of ultra-wealthy families from China looking to protect their wealth from a government that increasingly views them with suspicion. The Chinese Communist Party’s recent crackdowns on tech billionaires and tax-shy celebrities, as well as three years of “zero COVID” policies, have led many rich Chinese to look for a safe haven. Nervous over the fate of their fortunes, some of the country’s mega-rich have since booked tickets to Singapore, insiders said. The key Asian financial hub ticks all the boxes for relocating tycoons. Singapore has been ruled by one party for the past six decades, and labor strikes and
Sex worker Nina relies on an apartment in the Turkish city of Istanbul as a relatively safe space to meet clients, but the 29-year-old is worried about making enough to cover the rent after the landlord doubled the price. As a surge in inflation fuels a housing crisis in Turkey, LGBTQ+ sex workers like Nina say landlords are forcing them to accept huge rent hikes for fear of being evicted. Nina, who uses the pronouns they and them, worries about how they will pay the increased monthly rent of 8,000 Turkish lira (US$425.11) on top of rising bills. “There are gas, electricity, water,
SHARES DOWN: The top 10 companies all decreased in market value last year, due to COVID-19, Russia’s invasion of Ukraine, rising interest rates and global inflation Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) retained the top spot among the largest companies in the Asian supply chain in terms of market capitalization, Digitimes Research said. Citing its Asia Supply Chain Market Cap 100 rankings for last year, the research firm last week said TSMC’s market cap was US$378.45 billion, the highest among Asian suppliers, although it dropped by nearly US$200 billion during the year. The 34.3 percent fall in TSMC’s market cap was the largest decline of any company in the survey last year, but was typical of how many top-ranking companies fared. The top 10 in Digitimes’ rankings all saw